Stock Track | Veracyte Soars 13.77% in Pre-market on Strong Q1 Earnings Beat and Raised 2026 Guidance

Stock Track05-06

Veracyte's stock surged 13.77% in pre-market trading on Wednesday, following the release of its first-quarter financial results that significantly exceeded analyst expectations and the company's subsequent upward revision of its full-year outlook.

The diagnostic company reported quarterly non-GAAP earnings of $0.52 per diluted share, beating the FactSet consensus estimate of $0.33. Revenue for the quarter rose to $139.1 million from $114.5 million a year earlier, also surpassing the $130.4 million analysts expected.

Investor sentiment was further bolstered as Veracyte raised its 2026 revenue guidance to a range of $582 million to $592 million, up from its previous forecast of $570 million to $582 million. The positive developments were complemented by bullish analyst action, including Guggenheim reiterating a Buy rating and Leerink Partners raising its price target on the stock.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188723661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-06 20:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188723661","market":"hk","top_or_hot":-1,"title":"Stock Track | Veracyte Soars 13.77% in Pre-market on Strong Q1 Earnings Beat and Raised 2026 Guidance","media":"Stock Track","content":"<p>Veracyte's stock surged 13.77% in pre-market trading on Wednesday, following the release of its first-quarter financial results that significantly exceeded analyst expectations and the company's subsequent upward revision of its full-year outlook.</p><p>The diagnostic company reported quarterly non-GAAP earnings of $0.52 per diluted share, beating the FactSet consensus estimate of $0.33. Revenue for the quarter rose to $139.1 million from $114.5 million a year earlier, also surpassing the $130.4 million analysts expected.</p><p>Investor sentiment was further bolstered as Veracyte raised its 2026 revenue guidance to a range of $582 million to $592 million, up from its previous forecast of $570 million to $582 million. The positive developments were complemented by bullish analyst action, including Guggenheim reiterating a Buy rating and Leerink Partners raising its price target on the stock.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Veracyte Soars 13.77% in Pre-market on Strong Q1 Earnings Beat and Raised 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Veracyte Soars 13.77% in Pre-market on Strong Q1 Earnings Beat and Raised 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-06 20:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Veracyte's stock surged 13.77% in pre-market trading on Wednesday, following the release of its first-quarter financial results that significantly exceeded analyst expectations and the company's subsequent upward revision of its full-year outlook.</p><p>The diagnostic company reported quarterly non-GAAP earnings of $0.52 per diluted share, beating the FactSet consensus estimate of $0.33. Revenue for the quarter rose to $139.1 million from $114.5 million a year earlier, also surpassing the $130.4 million analysts expected.</p><p>Investor sentiment was further bolstered as Veracyte raised its 2026 revenue guidance to a range of $582 million to $592 million, up from its previous forecast of $570 million to $582 million. The positive developments were complemented by bullish analyst action, including Guggenheim reiterating a Buy rating and Leerink Partners raising its price target on the stock.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCYT","symbol_name":"Veracyte Inc","start_time":0,"source_url":"","article_id":"1188723661","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188723661","pubTimestamp":1778071943,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Veracyte's stock surged 13.77% in pre-market trading on Wednesday, following the release of its first-quarter financial results that significantly exceeded analyst expectations and the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VCYT":"Veracyte Inc"},"translate_title":"股票追踪|Veracyte盘前飙升13.77%，第一季度盈利强劲，并上调2026年指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCYT":1},"content_text":"Veracyte's stock surged 13.77% in pre-market trading on Wednesday, following the release of its first-quarter financial results that significantly exceeded analyst expectations and the company's subsequent upward revision of its full-year outlook.The diagnostic company reported quarterly non-GAAP earnings of $0.52 per diluted share, beating the FactSet consensus estimate of $0.33. Revenue for the quarter rose to $139.1 million from $114.5 million a year earlier, also surpassing the $130.4 million analysts expected.Investor sentiment was further bolstered as Veracyte raised its 2026 revenue guidance to a range of $582 million to $592 million, up from its previous forecast of $570 million to $582 million. The positive developments were complemented by bullish analyst action, including Guggenheim reiterating a Buy rating and Leerink Partners raising its price target on the stock.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188723661","isCrawlerRequest":true}